Novel heparin-activated protein kinase activity in rabbit skeletal muscle  by Ahmad, Zafeer et al.
Volume 179, number 1 FEBS 2097 January 1985 
Novel heparin-activated protein kinase activity in rabbit 
skeletal muscle 
Zafeer Ahmad, Anna A. DePaoli-Roach and Peter J. Roach* 
Department of Biochemistry, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46223, USA 
Received 23 August 1984; revised version received 27 October 1984 
A heparin-activated protein kinase has been identified in rabbit skeletal muscle. The enzyme, which had 
a native molecular mass of 70 kDa as judged by gel filtration, was stimulated 3- to 5-fold by heparin, half- 
maximally at 3 pg/ml heparin. The stimulation by heparin was not reproduced by other polyanions such 
as polyaspartate and polyglutamate. The protein kinase was detected by its ability to phosphorylate glyco- 
gen synthase; it was ineffective in phosphorylating caseins, phosvitin, histone, or phosphorylase. Glycogen 
synthase was phosphorylated to a stoichiometry of 0.7-0.8 phosphates/subunit, exclusively at serine residues 
located in the COOH-terminal CNBr-fragment of the subunit, with a corresponding reduction in the - / + 
glucosedP activity ratio from 0.96 to 0.43. The activity of the protein kinase was unaffected by the presence 
of Caz+ and/or phospholipid, cyclic AMP or heat-stable inhibitor protein of cyclic AMP-dependent protein 
kinase. The enzyme was inhibited about 60% by the presence of glycogen, half-maximal effect at 25 pg/ml. 
The heparin-activated protein kinase is clearly distinguishable from other known glycogen synthase kinases. 
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1. INTRODUCTION 
Covalent modification is one of the basic 
mechanisms that have evolved for the control of 
protein function (e.g., see [l-3]). During the last 
few years, it has become evident that cells contain 
numerous protein kinases (review, [4]). Previous 
studies in this laboratory have confronted the 
question of multiple protein kinases in an investi- 
gation of glycogen synthase, an enzyme shown to 
be phosphorylated in vitro by no fewer than eight 
different protein kinases [l-6]. Selective inhibitors 
and activators have proven useful in discriminating 
among protein kinases (e.g., cyclic nucleotides, 
Ca’+, calmodulin). The glucosaminoglycan 
heparin, for reasons as yet obscure, has also found 
application in this context. Heparin is a potent in- 
hibitor of enzymes of the casein kinase II class [7] 
and in [5] was also able to inhibit rabbit liver casein 
kinase I. Phosphorylase kinase was shown to be 
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activated by heparin [8,9] and recent work has also 
described a stimulation of cyclic AMP-dependent 
protein kinase [lo]. We report here the identifica- 
tion in rabbit muscle of a novel heparin-activated 
glycogen synthase kinase activity. 
2. EXPERIMENTAL 
2.1. Isolation of heparin-activated protein kinase 
The enzyme was identified during attempts to 
purify another protein kinase, designated FA/ 
GSK-3 (see [5,1 l]), from rabbit skeletal muscle 
using the method of [l 11. At the stage of chroma- 
tography on phosphocellulose, elution was ef- 
fected using a gradient of NaCl: the heparin-ac- 
tivated protein kinase eluted at 0.12 M NaCl and 
was separated from FA/GSK-3 which eluted at 
0.3 M NaCl. The heparin-activated enzyme was 
concentrated and subjected to chromatography on 
Sephadex G150, CM-Sephadex and finally Affigel 
blue. The specific activity of the enzyme in the 
presence of heparin was lo-12 nmol phosphate 
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transferred/min per mg. The preparation con- 
tained undetectable phosphorylase phosphatase 
activity. A native molecular mass of 70 kDa was 
estimated from gel filtration on Sephadex G200. 
The preparation was stored at - 70°C. 
2.2. Other materials and methods 
Protein kinase activity was measured using pub- 
lished methods [5] with 0.2 mg/ml rabbit skeletal 
muscle glycogen synthase as substrate and 
[y-32P]ATP at a specific activity of 1000 cpm/ 
pmol. For routine assays, heparin was present at 
10 pg/ml. Variations in conditions are noted in the 
text. Heparin, average molecular mass 12 kDa, 
was the generous gift of Drs P. Allison and N. 
Bang, Lilly Laboratory for Clinical Research, In- 
dianapolis. Polyglutamate and polyaspartate were 
from Sigma, St. Louis. Other materials and 
methods are described in [5,12]. 
3. RESULTS 
3.1. Dependence of protein kinase activity on 
heparin 
As shown in fig. 1, the enzyme was stimulated by 
heparin, with half-maximal activation at approx- 
imately 3 pg/ml. Maximal activation in the range 
3-5-fold was observed in this study. As a prelimi- 
nary test of whether the stimulation was related 
solely to the polyanionic nature of heparin, poly- 
glutamate (average M, 14000 and 20000) and poly- 
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Fig. 1. Heparin activation of the protein kinase. The rate 
of glycogen synthase phosphorylation was determined as 
a function of heparin concentration and is referred to 
the activity in the absence of heparin. 
aspartate (average M, 6000 and 32000) were tested 
as effecters of the enzyme. Neither polyamino 
acid, up to concentrations of lOOpg/ml, caused 
significant stimulation of the protein kinase. 
Features other than negative charge are thus in- 
volved in the activation. 
3.2. Substrate specificity and comparison with 
other protein kinases 
The activity of the protein kinase was tested with 
a number of potential substrates that we have used 
in characterizing other glycogen synthase kinases. 
Table I 
Effect of heat stable inhibitor on heparin-activated protein kinase 
and cyclic AMP-dependent protein kinase 
Enzyme Heparin Activity (nmol/min 
per assay)’ 
- inhibitorb + inhibitor 
Heparin-activated 
kinase 
- 0.76 0.84 
+ 2.72 3.0 
Cyclic AMP-dependent 
protein kinase 
(catalytic subunit) 
- 1.23 0.13 
+ 3.59 0.38 
a Glycogen synthase phosphorylation was assayed as in [5] 
b ‘Inhibitor’ refers to the heat-stable protein inhibitor of cyclic 
AMP-dependent protein kinase [131 
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These were phosvitin, @casein A and B, cusi-casein, 
x-casein, histone (Sigma type IIA and type IIIS), 
and glycogen phosphorylase from muscle. None of 
these proteins underwent detectable phosphoryla- 
tion by the heparin-stimulated protein kinase. The 
enzyme did, however, phosphorylate rat liver 
glycogen synthase (not shown). 
The protein kinase was not inhibited by the heat- 
stable inhibitor (131 of cyclic AMP-dependent pro- 
tein kinase (table l), and in fact slight activation 
was observed. In parallel assays, the cyclic AMP- 
dependent protein kinase was inhibited 90% by the 
inhibitor protein, whether or not heparin was pre- 
sent. The results of table 1 are also consistent with 
the report of [IO] that cyclic AMP-dependent pro- 
tein kinase was stimulated by heparin. In other ex- 
periments, it was established that the activity of the 
heparin-activated protein kinase was unaffected by 
cyclic AMP, Ca2’, or Ca” plus phosphatidyl 
serine and diacylglycerol (not shown). 
3.3. Phos~hory~ation of glycogen synthase 
The heparin-activated protein kinase phosphor- 
ylated glycogen synthase to a stoichiometry of 
0.7-0.8, with a corresponding reduction in the 
- / + glucose-6-P activity ratio from 0.96 to 0.43. 
The phosphate was associated exclusively with the 
glycogen synthase subunit (fig.2). Polyacrylamide 
gel electrophoresis of CNBr-fragments of the sub- 
strate indicated that the phosphate was contained 
in a single fragment of apparent molecular mass 
26 kDa (fig.2). From previous studies, this frag- 
ment, usually designated CB-2, is known to re- 
present he COOH-terminal region of the glycogen 
synthase subunit [3,12]. Only phosphoserine was 
detected in acid hydrolysates of glycogen synthase 
phosphorylated by the heparin activated protein 
kinase (not shown). 
3.4. Inhibition of heparin-activated protein kinase 
by glycogen 
Glycogen affects the activities of several glyco- 
gen synthase kinases (for example, [5]). It was 
found that glycogen also inhibited the phosphory- 
lation of glycogen synthase by the heparin-ac- 
tivated protein kinase (fig.3). The inhibition was 
not complete and was maximally 60-65%. Half- 
maximal effect was obtained at approximately 25 
pg/ml glycogen. These inhibition parameters were 
almost identical whether or not heparin was pre- 
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Fig.2. Electrophoretic analysis of phosphorylated 
glycogen synthase. Glycogen synthase was phosphoryl- 
ated by the heparin-activated protein kinase. The phos- 
phorylated enzyme was analyzed by PAGE in the 
presence of SDS (7% acrylamide) and an autoradiogram 
prepared (panel A). Tracks 1 and 2 correspond to 
enzyme phosphorylated in the absence (0.23) and 
presence (0.65) of heparin, respectively. The numbers in 
parentheses represent he degree of phosphorylation as 
phosphates/subunit. The two-digit numbers in the figure 
indicate the molecular masses (x 10m3) of standard 
proteins. Panel B shows an autoradiogram of an electro- 
phoretic analysis of CNBr-fragments prepared from 
glycogen synthase phosphorylated in the presence of 
heparin; note that in this case a 6-209’0 acrylamide 
gradient gel was used. The migration of the two 
phosphorylatable CNBr fragments of the enzyme are 
indicated by ‘CB-1’ and ‘CB-2’. 
sent, arguing that the unstimulated activity was 
associated with the same enzyme and not a con- 
taminant . 
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Table 2 
Comparison of glycogen synthase kinasesa 
Protein kinase Effect of Phosphorylation of 
muscle glycogen synthase 
Heparin Glycogen inb 
CB-1 CB-2 
Cyclic AMP-dependent 
protein kinase + 0 Yes Yes 
Phosphorylase kinase + + Yes No 
Protein kinase C 0 Yes Yes 
Calmodulin-dependent 
protein kinase 0 0 Yes Yes 
Casein kinase 1 _c Yes Yes 
Casein kinase 11 - No Yes 
PCo.4 0 0 Yes No 
FA/GSK-3 0 0 Yesd Yes 
Heparin-activated 
protein kinase + No Yes 
a Original citations can be obtained through [3-G] 
b The multiple phospho~lation sites of muscle glycogen synthase are mainly grouped 
in two CNBr-fragments, a smaller NHz-terminal fragment (CB-1) and a larger 
COOH-terminal fragment (CB-2) (see [31) 
’ At least, for the rabbit liver enzyme 151 
d A lesser phosphorylation of CB-1 was observed in [12] 
January 1985 
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Fig.3. Glycogen inhibition of the heparin-activated 
protein kinase. The protein kinase activity towards 
glycogen synthase was measured in the absence (squares) 
or presence (circles) of lO/cg/ml heparin and the 
indicated concentration of rabbit liver glycogen. 
4. DISCUSSION 
The results presented emonstrate the existence, 
in rabbit skeletal muscle, of a protein kinase ac- 
tivated 3-5-fold by heparin. The enzyme, of ap- 
parent native molecular mass 70 kDa, is specific 
for glycogen synthase among the substrates tested 
so far. The principal question then is whether this 
enzyme represents a novel protein kinase. It can be 
distinguished by several criteria from the eight 
other protein kinases known to phosphorylate 
glycogen synthase in vitro. First, it is the only 
glycogen synthase kinase that is activated by 
heparin but inhibited by glycogen (table 2). The 
specificity of the heparin-activated protein kinase 
in phosphorylating glycogen synthase only in the 
larger CNBr-fragment CB-2 distinguishes it from 
all the other enzymes except casein kinase II and 
possibly FJGSK-3 (table 2). The lack of recogni- 
tion of any casein variant as a substrate makes the 
enzyme different from all of the other enzymes ex- 
cept PC&. The insensitivity to CAMP, the Walsh 
inhibitor, Ca2+ and phospholipid indicates that the 
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enzyme is distinct from CAMP-dependent protein 
kinase, holoenzyme or catalytic subunit, phos- 
phorylase kinase or protein kinase C. On the basis 
of a native molecular mass of 70 kDa, the protein 
kinase is clearly distinguished from phosphorylase 
kinase, the calmodulin-dependent protein kinase, 
casein kinase II and possibly some of the other en- 
zymes. Therefore, the heparin-activated protein 
kinase is not related in any simple fashion to the 
known glycogen synthase kinases. For it to be 
derived from any of these enzymes, such as by pro- 
teolysis, would require not only a change in at least 
one effector interaction but also significant 
modification in substrate specificity. Nonetheless, 
definitive structural comparison of the enzyme 
with other protein kinases will require its purifica- 
tion to homogeneity. Efforts to achieve this are 
under way. 
The heparin-activated protein kinase thus 
represents a novel enzyme activity and the next 
question is to consider its possible physiological 
function. Glycogen synthase is phosphorylated by 
several protein kinases in vitro and the relative im- 
portance of these different enzymes in vivo is still 
a matter of active investigation. A priori, there is 
no reason yet to exclude the heparin-activated en- 
zyme as a physiologically relevant glycogen syn- 
thase kinase. Also, it may well be that further 
screening will uncover other important substrates 
for this protein kinase. Although heparin is not a 
strong candidate to be a physiological regulator, it 
may be mimicking some other relevant effector. 
From a practical standpoint, the present report is 
of special significance. In studies of glycogen syn- 
thase phosphorylation, it is necessary to recognize 
the existence of the heparin-activated protein 
kinase and to note that the inclusion of heparin in 
assays of Ca2+- and cyclic AMP-independent 
glycogen synthase kinases may not only inhibit ca- 
sein kinases I and II but could also activate this 
novel enzyme. Future studies must address a more 
detailed characterization of the heparin-activated 
protein kinase and its phosphorylation of glycogen 
synthase. 
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